Robert "Keith" Woods

Board Member

Equibles does not estimate personal net worth.

Get an email with a short summary when Neurogene Inc. publishes a filing, an earnings call transcript or a press release.

Get NGNE alerts

About Robert "Keith" Woods

Robert "Keith" Woods is recorded as Board Member at Neurogene Inc. (NGNE) since June 12, 2025. Neurogene Inc. reported in an 8-K filed June 12, 2025 that Robert "Keith" Woods was appointed Class II director, effective June 12, 2025. Neurogene Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Neurogene Inc. includes David J. Main (CEO), Donna M. Cochener (CEO), Rachel McMinn (CEO, Chairman and Board Member) and 7 others.

“Election of two Class II directors, Sarah B. Noonberg and Robert “Keith” Woods, each to serve until the 2028 annual meeting of stockholders and until their respective successors are elected and qualified”

Neurogene Inc. Form 8-K, filed June 12, 2025 · Read the filing

Affiliation history

Neurogene Inc. (NGNE)
Board Member

SEC 8-K

Current
2025-06-12–present

Company network

Neurogene Inc.

NGNE

Current role

Biotechnology · Healthcare

Board Member

2025-06-12–present

Leadership on record at Neurogene Inc.

David J. Main CEO
Donna M. Cochener CEO
Rachel McMinn CEO, Chairman, Board Member
Christine Mikail CFO, Board Member
Christine Mikail Cvijic CFO
Jonathan Drachman CFO
Robert Ho CFO
Sean Smith CFO, Chief Accounting Officer
Donna Cochener General Counsel
Cory Freedland Board Member

Recent activity

Executive change Appointed: Class II director Neurogene Inc. (NGNE)
2025-06-12